Home Research For Researchers Research Digest Etiology

New studies focused on genetic, environmental or lifestyle factors that influence risk.


Ambry to Present New Data Showing That up to 30% of Cancer Risk Carriers Are Missed by Current Testing Guidelines at the 2017 ASCO Meeting
ASCO abstract

  • Meeting: 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  • Institution(s): Beth Israel Deaconess Medical Center, Cambridge, MA, and others
  • Lead author(s): Mary Linton Bounetheau Peters
  • Major finding: Preliminary results show that 6.6% of unselected pancreatic ductal adenocarcinoma (PDAC) patients carry a germline mutation in a gene known to increase PDAC risk and 4.3% have a mutation in genes not previously linked to PDAC. Existing testing criteria did not identify 30% of carriers. Continued refinement of guidelines is necessary to align genetic testing with inherited PDAC risk.


Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.

shop purple logo

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2019 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.